PMID- 18500269
OWN - NLM
STAT- MEDLINE
DCOM- 20081022
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Print)
IS  - 0893-3952 (Linking)
VI  - 21
IP  - 8
DP  - 2008 Aug
TI  - Automated detection of genetic abnormalities combined with cytology in sputum is 
      a sensitive predictor of lung cancer.
PG  - 950-60
LID - 10.1038/modpathol.2008.71 [doi]
AB  - Detection of lung cancer by sputum cytology has low sensitivity but is 
      noninvasive and, if improved, could be a powerful tool for early lung cancer 
      detection. To evaluate whether the accuracy of diagnosing lung cancer by 
      evaluating sputa for cytologic atypia and genetic abnormalities is greater than 
      that of conventional cytology alone, automated scoring of genetic abnormalities 
      for 3p22.1 and 10q22.3 (SP-A) by fluorescence in situ hybridization (FISH) and 
      conventional cytology was done on sputa from 35 subjects with lung cancer, 25 
      high-risk smokers, and 6 healthy control subjects. Multivariate analysis was 
      performed to select variables that most accurately predicted lung cancer. A model 
      of probability for the presence of lung cancer was derived for each subject. 
      Cells exfoliated from patients with lung cancer contained genetic aberrations and 
      cytologic atypias at significantly higher levels than in those from control 
      subjects. When combined with cytologic atypia, a model of risk for lung cancer 
      was derived that had 74% sensitivity and 82% specificity to predict the presence 
      of lung cancer, whereas conventional cytology achieved only 37% sensitivity and 
      87% specificity. For diagnosing lung cancer in sputum, a combination of molecular 
      and cytologic variables was superior to using conventional cytology alone.
FAU - Katz, Ruth L
AU  - Katz RL
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX 77030-4009, USA. rkatz@mdanderson.org
FAU - Zaidi, Tanweer M
AU  - Zaidi TM
FAU - Fernandez, Ricardo L
AU  - Fernandez RL
FAU - Zhang, Jingpin
AU  - Zhang J
FAU - He, Weigong
AU  - He W
FAU - Acosta, Charisse
AU  - Acosta C
FAU - Daniely, Michal
AU  - Daniely M
FAU - Madi, Lea
AU  - Madi L
FAU - Vargas, Mary A
AU  - Vargas MA
FAU - Dong, Qiong
AU  - Dong Q
FAU - Gao, Xiaoying
AU  - Gao X
FAU - Jiang, Feng
AU  - Jiang F
FAU - Caraway, Nancy P
AU  - Caraway NP
FAU - Vaporciyan, Ara A
AU  - Vaporciyan AA
FAU - Roth, Jack A
AU  - Roth JA
FAU - Spitz, Margaret R
AU  - Spitz MR
LA  - eng
GR  - P50 CA070907/CA/NCI NIH HHS/United States
GR  - P50CA70907/CA/NCI NIH HHS/United States
GR  - N0 1 CN 85083 57/CN/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080523
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
SB  - IM
EIN - Mod Pathol. 2008 Aug;21(8):1065. Jiang, Xiaoying Gao Feng [corrected to Gao, 
      Xiaoying]; Jiang, Feng [added]
EIN - Mod Pathol. 2009 May;22(5):734-6
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Neuroendocrine/diagnosis/*genetics
MH  - Carcinoma, Squamous Cell/diagnosis/*genetics
MH  - *Chromosome Aberrations
MH  - *Chromosomes, Human, Pair 11
MH  - *Chromosomes, Human, Pair 3
MH  - Cytodiagnosis/methods
MH  - Female
MH  - Humans
MH  - Image Cytometry/methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Lung Neoplasms
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - ROC Curve
MH  - Sputum/cytology
PMC - PMC3377448
MID - NIHMS381583
COIS- Disclosure/Conflict of interest Drs Katz and Jiang are holders of an issued USA 
      patent (US Pat. Appl. No. 20060078885) for FISH probes to 3p22.1 and 10q22-23. Dr 
      Katz is a consultant to Bioview Company, Rehovoth, Israel, and performed this 
      study on a Bioview system on loan from Bioview to the Pathology Department, MD 
      Anderson Cancer Center. Bioview company has an option through the MD Anderson 
      Technology Office to license these probes.
EDAT- 2008/05/27 09:00
MHDA- 2008/10/23 09:00
PMCR- 2012/06/18
CRDT- 2008/05/27 09:00
PHST- 2008/05/27 09:00 [pubmed]
PHST- 2008/10/23 09:00 [medline]
PHST- 2008/05/27 09:00 [entrez]
PHST- 2012/06/18 00:00 [pmc-release]
AID - S0893-3952(22)02254-2 [pii]
AID - 10.1038/modpathol.2008.71 [doi]
PST - ppublish
SO  - Mod Pathol. 2008 Aug;21(8):950-60. doi: 10.1038/modpathol.2008.71. Epub 2008 May 
      23.